⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19347197 | 0.71 | — | — | |
| SCHEMBL4621674 | 0.67 | — | — | |
| SCHEMBL1617042 | 0.67 | — | — | |
| SCHEMBL5254237 | 0.67 | — | — | |
| SCHEMBL814784 | 0.67 | — | — | |
| SCHEMBL15564067 | 0.67 | — | — | |
| SCHEMBL15799651 | 0.65 | GLA (0.33) | — | |
| SCHEMBL23663312 | 0.62 | TSHR (0.34) | — | |
| SCHEMBL25128519 | 0.62 | GLA (0.45) | — | |
| SCHEMBL22744037 | 0.62 | KDM4E (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-30 | — | — | US | disclosed |
| CN-115485273-B | N- (heterocyclyl and heterocyclylalkyl) -3-benzyl pyridin-2-amine derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2024-08-13 | — | — | CN | disclosed |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4126849-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115485273-A | N- (heterocyclyl and heterocyclylalkyl) -3-benzylpyridin-2-amine derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021202775-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202775-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| CN-1222192-A | Antisense inhibitors of vascular endothelial growth factor (VEFG/VPF) expression | DEUTCH HOECHST MARIO ROSEL INC (DE) | 1999-07-07 | — | — | CN | disclosed |
| EP-0910634-A2 | ANTISENSE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEgF/VPF) EXPRESSION | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997039120-A2 | ANTISENSE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEFG/VPF) EXPRESSION | ARONEX PHARMACEUTICALS, INC. (US) | 1997-10-23 | — | — | WO | disclosed |